Efficacy and Safety of Aflibercept 8 mg in PULSAR Trial in Neovascular AMD

Opinion
Video

Dr. Marion Munk reviews the Phase 3 clinical trial of high-dose aflibercept (8 mg) in neovascular AMD, emphasizing how this new therapy could alleviate the treatment burden for patients while providing superior outcomes.

Newsletter

Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.

Subscribe Now!
Recent Videos
Related Content
AI-powered biomarker segmentation enhances precision in monitoring nAMD

AI-powered biomarker segmentation enhances precision in monitoring nAMD

Lynda Charters
April 20th 2025
Article
Aflibercept: Applications for dosing duration and additional indications pending decision with FDA and EMA

Aflibercept: Applications for dosing duration and additional indications pending decision with FDA and EMA

Sydney M Crago
April 16th 2025
Article
Biocon, Regeneron settle to launch aflibercept biosimilar, Yesafili in the US

Biocon, Regeneron settle to launch aflibercept biosimilar, Yesafili in the US

Martin David Harp
April 15th 2025
Article
New guidelines boost choriocapillaris imaging in AMD with SS-OCTA

New guidelines boost choriocapillaris imaging in AMD with SS-OCTA

Alessandro Berni, MD;Philip J. Rosenfeld, MD, PhD
April 14th 2025
Article
Seville, Spain, and the Giralda of Seville, in June 2018. Image credit: ©Julián Maldonado – stock.adobe.com

The Congress on Controversies in Ophthalmology (COPHy) highlights debates in surgical, medical retina

Hattie Hayes
April 4th 2025
Article
International study illuminates economic burden of late-stage age-related macular degeneration

International study illuminates economic burden of late-stage age-related macular degeneration

Lynda Charters
April 1st 2025
Article
© 2025 MJH Life Sciences

All rights reserved.